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Since the pioneering studies of Cohen on growth factors
(Cohen, 1986) and the identification of its homology to the
transforming protein encoded by the avian oncogene v-erbB,
the epidermal growth factor receptor (EGFR) has been the sub-
ject of intense investigation. Numerous studies have document-
ed the apparent importance of EGFR signaling on normal
development and neoplastic transformation and progression.
Most importantly for cancer therapeutics development, blocking
receptor signaling by antibodies to the extracellular ligand bind-
ing domain and small molecules to the tyrosine kinase (TK)
leads to the inhibition of cancer cell proliferation. Unfortunately,
clinical trials of EGFR targeting agents have yielded mixed
results to date. Objective tumor responses rates of 10%–18%
have consistently been reported from phase 2 studies of TK
inhibitors gefitinib and erlotinib in patients with non-small cell
lung cancer (NSCLC); however, the mechanisms leading to
tumor regression in this subset of patients and the means to
identify these patients prior to initiating therapy have been elu-
sive. Recently, two papers have described the identification of
genetic abnormalities in the EGFR kinase domain that predict
tumor response to gefitinib (Lynch et al., 2004; Paez et al.,
2004). That both groups identified mutations in the same region
of the receptor only heightens the excitement that the elusive
goal of targeting gefitinib, and possibly other EGFR inhibitors, to
patients most likely to benefit may be achieved.
EGFR signaling in cancer
EGFR, a 170 kDa membrane-spanning glycoprotein, is one of
four members of the human EGFR (HER) family. EGFR plays an
important role in organogenesis and in neoplastic processes of
cell proliferation, inhibition of apoptosis, angiogenesis, and
metastatic spread. Stimulation of the receptor through ligand
binding leads to receptor oligomerization at the plasma mem-
brane, activating the receptor TK and thereby causing transpho-
sphorylation of tyrosine residues in the intracellular part of the
receptor. These residues are docking sites for proteins contain-
ing Src homology domain 2 and phosphotyrosine binding
domains that, in turn, trigger a chain of biochemical reactions
through several signaling cascades that include the mitogen-
activated protein kinase (MAPK) and the phosphoinositide 3-
kinase (PI3K) Akt pathways, which transmit the growth stimuli to
the cell nucleus (Yarden and Sliwkowski, 2001).
The specificity and potency of the signaling output from
activated EGFR are highly dependent on the activating ligand
as well as the cellular levels of the coreceptors HER2/neu
(erbB2), HER3 (erbB3), and HER4 (erbB4), all of which can
oligomerize with the EGFR. EGFR, as well as other family mem-
bers and ligands, is commonly expressed in epithelial carcino-
mas and gliomas (Yarden and Sliwkowski, 2001). Receptor
expression by tumor cells has been linked with disease progres-
sion, poor survival, resistance to chemotherapy, and poor
response to therapy. Because of these characteristics, and
because agents that specifically inhibit receptor signaling also
inhibit tumor cell proliferation, EGFR has been viewed as a
rational target for antitumor therapy.
EGFR is the protein product of gene containing 28 exons
spanning approximately 200 kb found on chromosome 7p11.2
(Reiter et al., 2001). EGFR is the cellular protooncogene
homolog of the avian erythroblastosis virus v-erbB oncogene
(Downward et al., 1984). Aberrant signaling through EGFR can
lead to neoplastic transformation of human cells. For example,
expression of high levels of EGFR and its ligand, transforming
growth factor-α (TGFα), has been shown to induce transforma-
tion in vitro (Yarden and Sliwkowski, 2001). These studies have
suggested that overexpression of the wild-type receptor leads
to transformation only with ligand stimulation. Although EGFR is
widely expressed in human cancers, mutations in the receptor
are not common except in brain tumors. EGFR gene amplifica-
tion is detected in 40% of human glioblastomas, where a signif-
icant proportion also exhibits EGFR gene rearrangements
(Ekstrand et al., 1991). Other activating mutations have been
created in laboratory models (Sorokin, 1995), but the identifica-
tion of similar mutations in clinical cancers has been lacking.
Thus, the most frequent abnormality of EGFR reported in
human cancers to date is receptor overexpression.
EGFR in lung cancer
EGFR overexpression is frequently seen in non-small cell lung
cancer (NSCLC), the most common cause of cancer-related
death in the Western world. NSCLC collectively refers to the
subhistologies of squamous cell carcinoma (SCC), adenocarci-
noma (ADC), and large cell carcinoma, as well as the more
indolent bronchoalveolar carcinoma (BAC). After decades of
research, treatments for patients with metastatic NSCLC
remain unsatisfactory. Although combination chemotherapy
regimens improve survival, the effects are measured in weeks
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rather than many months or years. Only a handful of drugs
induce responses in more than 10% of patients, and responses
are rarely durable.
Given the poor outcomes with standard systemic therapies,
interest in identifying targets for therapeutics development in
lung cancer is intense, and EGFR appeared to be an appropri-
ate target due to the frequency of expression of the receptor
and ligand. EGFR protein overexpression was observed in 32%
to 79% of NSCLC (Hirsch et al., 2003; Mukohara et al., 2004;
Rusch et al., 1997) and occurred more frequently in SCC and
BAC than ADC or large cell carcinomas (Hirsch et al., 2003;
Mukohara et al., 2004; Rusch et al., 1997). Gene amplification
was seen in 9% of the patients by fluorescence in situ hybridiza-
tion. Coexpression of TGFα and EGFR was reported in 29%
and 38% of specimens, respectively. Interestingly, EGFR and
TGFα overexpression was observed in all tumor stages and his-
tological types, but was most frequently seen in SCC. The prog-
nostic value of EGFR for survival of patients with lung cancer
remains controversial; however, the results of a meta-analysis
of 14 studies suggest that it does not correlate with this out-
come (Meert et al., 2002).
Gefitinib in lung cancer
Given the lack of therapeutic options and the frequency of over-
expression of EGFR and its ligands in NSCLC, it is not surprising
that evaluating gefitinib (Iressa, AstraZeneca) in this common
and highly lethal disease was a priority. Initial phase 1 dose-find
and toxicity trials documented an objective response rate of 10%
among NSCLC patients (Baselga et al., 2002; Herbst et al.,
2002). This result was considered promising, because the agent
was thought to most likely inhibit proliferation, thus delaying
tumor progression rather than inducing tumor shrinkage, and
because the agent had induced objective responses in a group
of patients refractory to standard therapies.
As a result of these encouraging results, clinical develop-
ment progressed quickly. Two large phase 2 studies comparing
two doses of gefitinib were initiated; one accruing NSCLC
patients with one prior treatment, conducted predominately in
Japan and Europe, and the other trial conducted mainly in the
United States (US). In parallel, phase 1 trials confirmed the
safety of combining gefitinib with standard chemotherapy regi-
mens in newly diagnosed patients with advanced and metastat-
ic disease. These preliminary trials led to phase 3 trials
comparing the addition of gefitinib to chemotherapy. The trials
completed accrual within months, evidence of the perception
that this agent would likely be a therapeutic breakthrough.
Unfortunately, results of these studies were mixed. In ran-
domized phase 2 trials, response rates of 9.6% and 19% were
reported in the US- and Japanese-led trials, respectively
(Fukuoka et al., 2003; Kris et al., 2003). Although response
rates were low, they were often rapid in onset and durable.
Interestingly, differences in response rates for the 250 and 500
mg doses were not apparent. Despite evidence of modest sin-
gle agent activity, phase 3 trials evaluating the addition of gefi-
tinib to chemotherapy as first-line therapy in patients with
metastatic NSCLC failed to show an advantage in response
rate, progression-free survival, or overall survival compared to
standard treatment (Giaccone et al., 2004; Herbst et al., 2004).
The consistent response rates in patients with chemotherapy-
refractory disease and favorable safety profile reported from the
single agent studies led to the approval of the gefitinib in Japan
in 2002 and the United States in 2003 (Cohen et al., 2004).
At the time of approval of gefitinib, there was little under-
standing of the predictive markers of drug activity. Retrospective
analyses of patients receiving single agent gefitinib showed that
responses were more frequent among patients who had never
smoked, women, and patients with BAC or ADC with bron-
choalveolar features (Fukuoka et al., 2003; Janmaat et al.,
2003; Kris et al., 2003; Miller et al., 2004; Nishiwaki et al., 2004).
However, there was no correlation between the intensity of
immunohistochemical staining of the tumor for EGFR and the
presence or absence of a response, and no obvious candidate
biomarker to select patients for treatment with gefitinib.
The discovery of markers of gefitinib sensitivity
Research into the identification of biomarkers that correlate to
clinical benefit or resistance to gefitinib has been intense. The
first reports of a predictive marker for drug sensitivity have
recently been published (Lynch et al., 2004; Paez et al., 2004).
Both groups started with the simple hypothesis that patients
with dramatic responses to gefitinib were likely to have tumors
harboring genetic alterations in specific kinases, as is the case
for imatinib mesylate treatment of c-kit mutant gastrointestinal
stromal tumors and trastuzumab treatment of HER2 amplified
breast carcinoma. Both groups sequenced the EGFR gene from
lung cancer specimens from patients treated and not treated
with gefitnib as well as normal lung tissue to identify mutations,
and subsequently evaluated the biochemical effects of the
mutations in vitro. Results from these groups are consistent and
complementary.
Paez and colleagues (Paez et al., 2004) started their search
by sequencing the exons encoding the activation loops of 47 of
58 human receptor TK genes from a subset of 58 NSCLCs and
subsequently narrowed their evaluation to the EGFR TK
domain. The identified mutations were found in 15 of 58 unse-
lected tumors from Japan and one of 61 from the United States
(Paez et al., 2004). These mutations were heterozygous, and
more common in women, ADC, and Japanese patients.
Mutations were identified in 5/5 patients who responded and 0/4
patients who did not respond to gefitinib.
Lynch and colleagues sequenced the entire coding region
of the EGFR gene from tumor specimens from nine patients
treated with gefitinib with clinical responses, then screened
additional tumor specimens and cell lines for mutations (Lynch
et al., 2004). Somatic mutations were identified in the TK
domain of the EGFR gene in eight of nine patients with gefitinib-
responsive lung cancer, as compared with none of the seven
patients without a response (Lynch et al., 2004). Similar muta-
tions were detected in tumors from two of 25 patients with pri-
mary NSCLC not exposed to gefitinib. However, mutations were
not identified in primary breast, colon, kidney, pancreas, and
brain tumor specimens or in 108 cancer cell lines.
In both studies, mutations were identified in the EGFR TK
domain, with the majority of abnormalities clustering within
exons 19 and 21. Mutations were either small, in-frame dele-
tions or amino acid substitutions clustered around the adeno-
sine triphosphate (ATP) binding pocket. Substitution mutations
changing leucine 858 to arginine (L858R), guanine 719 to ser-
ine (G719S), and leucine 861 to glutamine (L861Q), as well as
multiple deletion mutations clustered in the region spanning
codons 746 to 759 within the kinase domain, were reported.
These alterations cluster around the active site of the kinase,
with the substitution mutations laying in the activation loop and
glycine-rich P loop, which are important for autoregulation
(Lynch et al., 2004; Paez et al., 2004).
The biological consequences of some of these mutations
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were investigated in vitro. Paez and colleagues found that the
H3255 cell line, which harbors the L858R mutations, was 50-
fold more sensitive to gefitinib than other adenocarcinoma cell
lines, with an IC50 of 40 nM for cell survival. Treatment with 100
nM gefitinib completely inhibited EGFR autophosphorylation,
as well as phosphorylation of downstream targets extracellular
signal-regulated kinase 1/2 (ERK1/2) and AKT kinase. Lynch
and colleagues reported similar results from studying Cos-7
cells transiently expressing wild-type and mutant EGFR. In the
absence of serum, neither wild-type nor mutant EGFR demon-
strated autophosphorylation. However, activation of mutant
EGFRs was greater in the presence of EGF stimulation, and
mutant EGFR downregulation was significantly slower com-
pared to wild-type EGFR. Compared to wild-type receptors,
mutant receptors were more sensitive to inhibition by gefitinib
with IC50 and IC100 of 0.1 µM and 2.0 µM versus 0.015 µM and
0.2 µM, respectively.
What conclusions may be drawn from these two papers?
First, mutations clustering around the EGFR TK domain appear
to augment ligand-induced EGFR autophosphorylation and
confer increased sensitivity to gefitinib. These results suggest
that agents such as antibodies, which inhibit ligand binding as
well as small molecule ATP-mimetics that, like gefitinib, bind to
the ATP pocket, may benefit patients with tumors that harbor the
EGFR mutations. Second, within the limits of the number of
specimens analyzed, it appears that most responses (totaling
13/14 between the two papers) are associated with these muta-
tions. Third, EGFR mutations are more common in ADC and
BAC histologies, nonsmokers, and Japanese patients, suggest-
ing a much different etiology for lung cancers developing in
these groups compared to squamous cell carcinomas, smok-
ers, and non-Japanese patients.
Future directions
Many questions remain to be answered regarding the biochem-
ical and cellular effects of the various mutations, the prevalence
and natural history of EGFR mutated lung cancers in ethnically
diverse populations, and the responsiveness of EGFR-mutated
and -nonmutated lung cancers to gefitinib and other EGFR-tar-
geting small molecules and antibodies.
There are two main modes of signal attenuation defined for
EGFR (Carpenter, 2000; Schlessinger, 2003).The first is ligand-
induced internalization and subsequent degradation, a process
that occurs over the 15–30 min after EGFR ligand binding and
persists for hours.The second involves rapid dephosphorylation
of activated EGFR within seconds to minutes, which reverts the
receptor to an inactive state in the absence of persistent ligand
(Carpenter, 2000; Schlessinger, 2003). Both phenomena atten-
uate EGFR signaling and may be influenced by not only the
presence of mutations around the EGFR TK domain, but also
the types of mutations in these areas. Thus, specific mutations
may result in different strengths of EGFR signaling, as well as
different responses to gefitinib and other EGFR inhibitors.
Further structure-activity studies will likely identify the important
features of the interactions between mutated EGFR and EGFR
inhibitors and may lead to the design of more potent inhibitors.
The higher frequency of mutations in lung cancer patients
from Japan versus the United States is interesting. Lung cancer
is the leading cause of death among cancer patients in Japan
as well as the United States. However, its age-adjusted mortali-
ty and incidence rates are still less than two-thirds of those in
the US (Stellman et al., 2001;Yoshimi et al., 2003). Studies from
Japan and Western countries suggest that while smoking
shows a dose-response relationship with all lung cancer cell
types, its association is less predominant for ADC than for SCC
(Barbone et al., 1997; Kabat, 1996), and particularly for ADC in
women (Marugame et al., 2004). It has been postulated that
specific Japanese dietary factors may protect against cancer
development in subsets of patients (Takezaki et al., 2001).
However, these factors may not protect against the
development of lung cancers with EGFR mutations. Clearly, the
etiologic factors predisposing to EGFR-mutated lung cancer
specifically and lung cancers in nonsmokers as a group require
further elucidation.
The correlation between sensitivity to EGFR inhibitors and
nonsmoking status also suggest that chemoprevention strate-
gies based on EGFR inhibition in high risk smokers or former
smokers may not be as effective as previously hoped.
Nonetheless, EGFR overexpression occurs early in the devel-
opment of smoking-related premalignant lesions, and thus,
evaluating EGFR inhibitors in precancerous disease, where
inhibition may have a greater impact on progression to cancer,
should not be abandoned prematurely.
The frequencies of these EGFR mutations, as well as their
biological and clinical consequences, will also need clarifica-
tion. Results from the studies to date suggest that EGFR muta-
tions and objective tumor responses are less common in
non-Japanese patients, smokers, and non-ADC histologies, but
more accurate estimates of the frequencies of mutations among
these diverse populations, and frequencies among patients with
different stages of disease are required. In addition, the natural
history of EGFR-mutated lung cancer and its response to stan-
dard therapies, gefitinib, and other EGFR inhibitors need to be
determined to optimize treatment strategies.
In addition to more accurately determining the frequency
and types of mutations in patients with lung cancer, it will be
important to determine the robustness of the correlation
between the mutations and patient benefit. The reported fre-
quencies of the EGFR mutations in random tumor specimens
assessed to date are low relative to the response rates from tri-
als of gefitinib in metastatic disease. This apparent discrepancy
may, in part, be due to the mutations appearing more frequently
among patients with recurrent and/or metastatic disease com-
pared to newly diagnosed, resectable patients. For example, if
the tumor specimens analyzed in the studies by the groups
were predominately from resected patients with early-stage dis-
ease, and the mutations increase the risk of relapse, then muta-
tions may be more common among patients with advanced
metastatic disease. Alternatively, these mutations may not iden-
tify all patients who may benefit from gefitinib, which seems like-
ly, given that at least one of the nine responding patients
assessed by Lynch and colleagues did not have an identifiable
mutation. Conversely, the presence of these mutations may not
correlate as strongly with objective tumor responses as appears
from these initial studies if additional abnormalities modify the
enhanced EGFR signaling conferred by mutant EGFR. Thus,
the true predictive value of the presence/absence of the differ-
ent mutations and clinical benefit of treatment with gefitinib and
other EGFR inhibitors will require additional evaluation. If there
is a strong correlation between the presence of mutated EGFR
and clinical benefit, and the magnitude of benefit is comparable
or superior to standard chemotherapy, then gefitinib would be a
reasonable alternative therapy for these patients.
At the moment, it appears that the presence of the
described EGFR mutations will identify NSCLC patients with
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the highest likelihood of responding to gefitinib. However, other
as yet unidentified factors may confer sensitivity to gefitinib
resulting in either responses or delayed progression. Erlotinib,
another small molecule EGFR TK inhibitor, was recently found
to extend survival compared to placebo among metastatic
NSCLC patients (Genentech Press Release, Tarceva Extends
Survival of Patients with Relapsed Non-Small Cell Lung Cancer,
April 25, 2004, http://www.gene.com/gene/news/press-releases/
display.do?method=detail&id=7387). This result suggests that
EGFR inhibition may confer a survival advantage in a patient
population unselected for the presence of EGFR mutations. If
benefit from treatment were limited only to patients with the
reported EGFR mutations, currently estimated to occur in 8% or
less of NSCLC patients, either the magnitude of the effect in this
subset of patients would have to be very large to lead to a posi-
tive result in an unselected patient population, or there are other
factors determining benefit to additional patients. If tumor speci-
mens from patients enrolled in this trial can be retrieved and
analyzed, the frequency as well as prognostic and predictive
importance of the EGFR mutations, and possibly other biomark-
ers, can be identified.
The investigators identifying the first biomarkers predictive
of sensitivity to gefitinib are to be congratulated. By detailed
investigation of the target, they have identified a subset of lung
cancer patients that may substantially benefit from treatment
with the EGFR inhibitor. Identification of other markers of sensi-
tivity and resistance to EGFR inhibitors relevant to lung cancer
as well as other epithelial cancers and brain tumors will
undoubtedly identify treatments and treatment strategies to
maximize the benefit to patients.
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